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Abstract
The CYP24A1  gene encodes 1,25-hydroxyvitamin-D3-24-hydroxylase,  a key enzyme
responsible for the catabolism of active vitamin D (1,25-dihydroxyvitamin D3). Loss-of-
function mutations in CYP24A1 lead to increased levels of active vitamin D metabolites.
Clinically, two distinct phenotypes have been recognised from this: infants with CYP24A1
mutations  present  with  infantile  idiopathic  hypercalcaemia,  often  precipitated  by
prophylactic  vitamin D supplementation.  A separate phenotype of  nephrolithiasis,
hypercalciuria and nephrocalcinosis often presents in adulthood. CYP24A1 mutations
should be suspected when a classical biochemical profile of high active vitamin D
metabolites, high or normal serum calcium, high urine calcium and low parathyroid
hormone is detected. Successful treatment with fluconazole, a P450 enzyme inhibitor, has
been shown to be effective in individuals with CYP24A1 mutations. Although CYP24A1
mutations are rare, early recognition can prompt definitive diagnosis and ensure treatment
is commenced.
Keywords: CYP24A1, vitamin D, hypercalcaemia, idiopathic infantile hypercalcaemia,
nephrolithiasis
1. Introduction
The supplementation of formula milk with vitamin D3 (cholecalciferol) prompted a rise in
infants presenting with symptomatic hypercalcaemia in the United Kingdom during the
1950s [1]. While this public health initiative was proving highly successful in preventing
rickets, for the small cohort of infants presenting with failure to thrive, dehydration and
nephrocalcinosis, the consequences of their hypercalcaemia were at times fatal. A diagnosis
of  idiopathic  infantile  hypercalcaemia  was  given  to  many  in  this  cohort.  The  apparent
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increased susceptibility of this minority group to vitamin D toxicity prompted research into
a genetic predisposition. Fifty-nine years later, CYP24A1 mutations were identified demon‐
strating  loss-of-function  mutations  encoding  1,25-hydroxyvitamin  D3  24-hydroxylase,  an
enzyme with a key role in vitamin D metabolism [2].
More recently, CYP24A1 mutations have been recognised in an adult population of patients
presenting with calcium-containing renal stones. On investigation, these patients typically
displayed hypercalciuria, nephrocalcinosis and occasionally chronic kidney impairment.
Vitamin D supplementation was not a feature in all cases [3], demonstrating a clinically
significant phenotype manifesting from normal dietary vitamin D intake. Importantly, some
patients had been symptomatic for many years, undergoing extensive investigations before a
diagnosis was made. A continuing focus on preventative medicine, including oral vitamin D
supplementation for maintenance of bone health and during pregnancy, is likely to continue
to risk triggering manifestations of vitamin D toxicity in individuals carrying biallelic muta‐
tions in CYP24A1. As diagnostic tests and successful treatments are starting to emerge, it is
important to recognise clinical presentations which should prompt screening for CYP24A1
deficiency [4–6].
2. CYP24A1 and the vitamin D pathway
The crucial role of vitamin D in calcium and phosphate homeostasis means excessive levels of
its active form can precipitate symptomatic hypercalcaemia. The activation of vitamin D takes
place in two stages. The first stage takes place in the liver: vitamin D3 is converted to 25-
hydroxyvitamin D3, a reaction catalysed by 25-hydroxylase (CYP2R1). The second stage occurs
in the kidney, when 25-hydroxyvitamin D3 is hydroxylated to 1,25-dihydroxyvitamin D3, the
active form. This stage is catalysed by 1α-hydroxylase, an enzyme encoded by the CYP27B1 [2].
Figure 1. Vitamin D metabolism pathway. Activation of Vitamin D: 1. Stage 1 occurs in the liver. Vitamin D3 is convert‐
ed to 25-hydroxyvitamin D3 by the enzyme 25-hydroxylase. The CYP2R1 gene encodes 25-hydroxylase. 2. Stage 2 oc‐
curs in the kidney. 25-hydroxyvitamin D3 is converted to 1,25-dihydroxyvitamin D3 by the enzyme 1α-hydroxylase.
The CYP27B1 gene encodes 1α-hydroxylase. 1,25-dihydroxyvitamin D3 is the physiologically most active form of vita‐
min D3 which binds to the vitamin D receptor. Inactivation of Vitamin D: Several hydroxylation steps occur in the ca‐
tabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. The first of these steps is catalysed by the enzyme 1,25-
hydroxyvitamin-D3-24-hydroxylase, which is encoded by the CYP24A1 gene.
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The inactivation of vitamin D metabolites relies upon two pathways which both include steps
catalysed by 1,25-hydroxyvitamin-D3-24-hydroxylase; CYP24A1 encodes this mitochondrial
enzyme which is part of the cytochrome P450 system [6]. The enzyme is present in vitamin D
target cells, predominantly located in the intestine and kidneys (Figure 1) [5].
2.1. Phenotypes
2.1.1. Idiopathic infantile hypercalcaemia
The first recognised phenotype of CYP24A1 mutations was in infants diagnosed with idio‐
pathic infantile hypercalcaemia. These individuals presented with vomiting, dehydration,
fevers and failure to thrive. On investigation, a typical biochemical profile of high serum
calcium and suppressed parathyroid hormone levels emerged. Renal ultrasound often
demonstrated nephrocalcinosis, deposition of calcium salts within the kidney. It was not
initially known whether the underlying pathophysiology of idiopathic infantile hypercalcae‐
mia (IIH) was due to excess production of vitamin D metabolites, or an inability to inactivate
vitamin D. A candidate gene approach was used to investigate families with typical presen‐
tations of idiopathic infantile hypercalcaemia. This research revealed a recessive loss-of-
function mutation, in which patients with CYP24A1 mutations were unable to inactivate
vitamin D as they were deficient in the enzyme catalysing this pathway (1,25-hydroxyvitamin-
D3-24-hydroxylase). Affected children presented either after sustained low-dose vitamin D
prophylaxis or directly following bolus doses of vitamin D. One sibling in which vitamin D
prophylaxis was avoided was proven to carry the same mutation but had remained clinically
silent. This supported evidence directly linking exogenous vitamin D supplementation with
precipitation of symptomatic hypercalcaemia [2].
2.1.2. Adult nephrolithiasis
Hypercalciuria is the most common cause of calcium-containing kidney stones. The recogni‐
tion that 40–45% of patients with idiopathic hypercalciuria have at least one relative with
nephrolithiasis implicates a genetic predisposition in many cases [4]. CYP24A1 mutations
have now been proven in a cohort of adults presenting with nephrolithiasis, hypercalciuria,
nephrocalcinosis and intermittent hypercalcaemia [4]. These patients had undergone exten‐
sive investigations before the cause of their nephrolithiasis was known, and multiple stone
episodes and nephrocalcinosis may lead to progressive chronic kidney disease (CKD) [7].
This is important in highlighting the potential clinical spectrum of the phenotype, which
may manifest without the trigger of vitamin D exposure. A typical biochemistry profile was
found within this phenotype group, with normal/high serum calcium levels, suppressed
parathyroid hormone, high levels of active vitamin D metabolites (25-hydroxyvitamin D3
and 1,25-dihydroxyvitamin D3) and low levels of inactivated vitamin D (24,25-dihydroxyvi‐
tamin D3). A recent study screening patients with known calcium nephrolithiasis for
CYP24A1 mutations did not identify any biallelic variants in a cohort of 166 patients, sug‐
gesting CYP24A1 mutations are a rare cause of idiopathic nephrolithiasis [8]. However, giv‐
en our increased understanding of this phenotype, it is imperative that recognition of the
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typical biochemical pattern (suppressed PTH, hypercalcaemia, hypercalciuria) in any pa‐
tients with nephrolithiasis prompts investigation for CYP24A1 mutations [4, 6, 8]. Establish‐
ing a molecular diagnosis in this small cohort of patients can facilitate correct treatment and
lifestyle modification (Table 1) [9].
Clinical features Biochemical profile
Idiopathic infantile hypercalcaemia:
• Vomiting
• Dehydration
• Failure to thrive
• Fever
• Adult presentation:
• Nephrolithiasis
• Nephrocalcinosis
• ↑ 25-hydroxyvitamin D3
• ↑ 1,25-dihydroxyvitamin D3
• ↓ 24,25-dihydroxyvitamin D3
• ↑ or high normal serum calcium
• ↑ urine calcium
• ↓ parathyroid hormone
Table 1. Key features of CYP24A1 mutation phenotypes.
2.1.3. Investigation
In patients with CYP24A1 mutations, an elevation in total vitamin D levels is typically seen.
In particular, 1,25-dihydroxyvitamin D3 levels are increased, but this assay is not routinely
performed in many laboratories. Conversely, serum 24,24-dihydroxyvitamin-D3 levels are
sometimes low or undetectable in patients with CYP24A1 mutations. A blood test that
calculates the ratio between vitamin D metabolites could be utilised in future clinical practice
as a screening tool for CYP24A1 mutations in those patients presenting with a typical bio‐
chemical profile. In the first study of this, Molin et al. used liquid chromatography–tandem
mass spectrometry to calculate the ratio of active to inactive vitamin D metabolites: Molar ratio
(R) of 25-hydroxyvitamin-D3: 24,25-dihydroxyvitamin D3. A large increase in the ratio of active
to inactive vitamin D metabolites, usually R > 80, was demonstrated in subjects who had
biallelic mutations resulting in loss of function of CYP24A1. Importantly, through use of a ratio
calculation, this test can avoid misleading results in patients who might have low 24,24-
dihydroxyvitamin-D3 levels due to vitamin D deficiency [6].
2.2. CYP24A1 variants
Several different loss-of-function mutations have now been identified within the CYP24A1
gene. The mutations are reported to be inherited in an autosomal recessive pattern, although
it is not yet clear whether partial penetrance or environmental factors may alter manifesta‐
tion of a recognised phenotype. One study showed individuals with biallelic mutations pre‐
sented with the clinically recognised phenotype and that heterozygous carriers were not
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sufficient to manifest clinical disease. However, it was hypothesised that infants with hap‐
loinsufficiency/heterozygous variants may be more sensitive to hypercalcaemia during
childhood while the kidney is still developing, and this could become relevant in consider‐
ing additional vitamin D supplementation which might overwhelm the 1,25-hydroxyvita‐
min-D3-24-hydroxylase enzyme pathway in this cohort (Table 2) [4, 6].
Year mutation 
reported
Age at
presentation
Phenotype CYP24A1 mutation  Reference
2011 6 months IIH A475fsX490 homozygote Schlingmann et al. [2]
2011 6 months IIH delE143 and E151X Schlingmann et al. [2]
2011 Asymptomatic Identified on family
screening
delE143 and E151X Schlingmann et al. [2]
2011 8 months IIH L409S and R396W Schlingmann et al. [2]
2011 Asymptomatic Identified on family
screening
L409S and R396W Schlingmann et al. [2]
2011 11 months IIH delE143 and R159Q Schlingmann et al. [2]
2011 7 months IIH E322K and R396W Schlingmann et al. [2]
2011 3.5 months IIH E322K and R396W Schlingmann et al. [2]
2011 7 weeks IIH R396W homozygote Schlingmann et al. [2]
2011 5 weeks IIH Complex deletion Schlingmann et al. [2]
2012 10 months IIH Homozygous delE143 Dauber et al. [10]
2012 44 years Intermittent
hypercalcaemia,
hypercalciuria,
nephrolithiasis
2 canonical intron-exon
splice junction mutations
(IVS5 +1G>A and IVS6
-2A>G)
Tebben et al. [11]
2013 4 months IIH Homozygous R396W Fencl et al. [12]
2013 9 years Nephrocalcinosis,
nephrolithiasis
Homozygous delE143 Dinour et al. [4]
2013 19 years Nephrolithiasis,
nephrocalcinosis, bladder
calcification
Compound
heterozygous
L409S and W268X
Dinour et al. [4]
2013 13 years Nephrolithiasis,
nephrocalcinosis,
hypercalcaemia,
hypercalciuria
Compound
heterozygous
L409S and W268X
Dinour et al. [4]
2013 9 years Nephrocalcinosis,
hypercalciuria
Compound
heterozygous
delE143 and L148P
Nesterova et al. [5]
2013 25 years Nephrolithiasis,
hypercalcaemia,
hypercalciuria
Compound
heterozygous
delE143 and L409S
Nesterova et al. [5]
2013 4.5 months IIH Homozygous R396W Skalova et al. [13]
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Year mutation 
reported
Age at
presentation
Phenotype CYP24A1 mutation  Reference
2013 3 months IIH followed by adult
presentation with
nephrocalcinosis, CKD,
hypercalcaemia and
hypercalciuria
Homozygous W210R Meusburger et al. [14]
2014 ~20 years Nephrolithiasis,
hypercalcaemia,
hypercalciuria
Homozygous delE143 Jacobs et al. [15]
2015 10 years Nephrolithiasis,
hypercalcaemia,
hypercalciuria
Homozygous delE143 Sayers et al. [7]
2015 45 years Nephrocalcinosis,
hypercalcaemia,
hypercalciuria
Compound
heterozygous
G469Afs*22 and P21R
Figueres et al. [19]
2015 32 years Nephrolithiasis,
nephrocalcinosis,
hypercalcaemia,
hypercalciuria
Compound
heterozygous L409S and
R157W
Figueres et al. [19]
2015 28 days IIH Compound
heterozygous
R157W and M374T
Figueres et al. [19]
2015 2 months IIH Compound
heterozygous
L409S and R396W
Figueres et al. [19]
2015 6 months IIH Homozygous L409S Figueres et al. [19]
2015 2 months IIH Compound
heterozygous
R396W and R396G
Figueres et al. [19]
2015 6 months IIH Compound
heterozygous
delE143 and L409S
Figueres et al. [19]
2015 1 day Hypercalcaemia, apnoea Heterozygous M374T Molin et al. [6]
2015 3 days Infection, hypercalcaemia,
suppressed PTH
Heterozygous M374T Molin et al. [6]
2015 11 days Prematurity,
hypercalcaemia,
suppressed PTH
Heterozygous G322A Molin et al. [6]
2015 4 days Prematurity,
hypercalcaemia,
suppressed PTH
Heterozygous R439C Molin et al. [6]
2015 13 days Small for gestational age,
hypercalcaemia,
suppressed PTH
Heterozygous M374T Molin et al. [6]
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Year mutation 
reported
Age at
presentation
Phenotype CYP24A1 mutation  Reference
2015 24 years Hypercalcaemia,
suppressed
PTH,
nephrocalcinosis,
CKD
Homozygous delE143 Jobst-Schwan et al. [3]
2015 Asymptomatic Identified on family
screening
Homozygous delE143 Jobst-Schwan et al. [3]
2015 26 years Nephrocalcinosis,
hypercalcaemia,
hypercalciuria
Homozygous delE143 Tray et al. [16]
2015 21 years Nephrocalcinosis,
nephrolithiasis,
hypercalcaemia
Heterozygous delE143
and R396W
Tray et al. [16]
2015 5 months IIH Compound
heterozygous
R396W and W134G
Dinour et al. [17]
2015 9 months IIH Compound
heterozygous
G315X and W134G
Dinour et al. [17]
2015 5 months IIH Homozygous delE143 Dinour et al. [17]
2015 35 years Nephrolithiasis,
nephrocalcinosis
and hypercalcaemia
during
pregnancy
Homozygous delE143 Dinour et al. [17]
CKD, chronic kidney disease; IIH, idiopathic infantile hypercalcaemia; PTH, parathyroid hormone.
Table 2. Identified mutations in CYP24A1.
2.3. Treatment
CYP24A1 mutations lead to calcium stone formation, and conventional treatments for calcium
stones are recommended. These would include maintaining a high fluid intake and avoiding
excess dietary sodium. Specific measures would include avoiding dietary vitamin D supple‐
ments (in foods and drinks) and avoidance of excessive sunlight exposure [7]. Ketoconazole
was first demonstrated as an effective treatment for reducing the effects of vitamin D toxicity
in patients with CYP24A1 mutations. As a non-specific P450 enzyme inhibitor ketoconazole
inhibits the enzyme catalysing production of 1,25-dihydroxyvitamin D3, (1α-hydroxylase),
thereby decreasing levels of active vitamin D3. However, CYP24A1-deficient individuals
require lifelong treatment as they will always lack the enzyme to inactivate vitamin D, and the
side-effect profile of ketoconazole, which includes hepatotoxicity, hypogonadism and adrenal
insufficiency, makes it unsuitable for this purpose [4]. More recently, low-dose fluconazole,
also acting as a P450 enzyme inhibitor, has been shown to reduce serum calcium levels and
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urinary calcium excretion in a patient with CYP24A1 mutation. It is likely that this drug,
alongside lifestyle modifications such as avoiding excess sun exposure and following a low
calcium and oxalate diet, will become the main treatment offered to patients diagnosed with
CYP24A1 mutations (Figure 2) [7, 18, 19].
Figure 2. Chemical structures of ketoconazole, an imidazole antifungal agent, and fluconazole, a triazole antifungal
agent. Azole agents are cytochrome inhibitors primarily used as antifungal agents. They are heterocyclic ring com‐
pounds and are generally classified as either imidazoles (e.g. ketoconazole) or triazoles (e.g. fluconazole), containing
two or three nitrogen atoms, respectively, in the azole ring. They exhibit their antifungal action through inhibition of
lanosterol 14-α demethylase, a cytochrome P450 enzyme important for the synthesis of a fungal plasma membrane
constituent.
2.4. Evidence for genetic heterogeneity of idiopathic infantile hypercalcaemia
Since the discovery of CYP24A1 mutations underlying idiopathic infantile hypercalcaemia
(IIH) in 2011, a cohort of IIH patients has been identified without CYP24A1 mutations. In 2015,
a new loss-of-function mutation in SLC34A1, which encodes the renal sodium–phosphate
cotransporter 2A (NaPi-IIa), was recognised in this group [20]. These patients presented with
a classical IIH phenotype, with symptoms of hypercalcaemia. Importantly, however, their
symptoms did not resolve with removal of vitamin D supplementation. Instead, their hyper‐
calcaemia corrected rapidly after commencing phosphate replacement, highlighting the
different mechanism driving the hypercalcaemia. In patients with SLC34A1 mutations, renal
phosphate wasting leads of inappropriately high levels of 1,25-dihydroxyvitamin-D3, which
in turn causes hypercalcaemia. It is crucial to distinguish between patients carrying mutations
in CYP24A1 versus SLC43A1, as different intervention is required to successfully treat their
hypercalcaemia [20]. As SLC34A1 mutations have also been identified as a cause of nephroli‐
thiasis, there is overlap between SLC34A1 and CYP24A1 mutation phenotypes in both
paediatric and adult presentations [21].
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3. Conclusions
Overall, CYP24A1 mutations are rare and account for a small proportion of symptomatic
hypercalcaemia or nephrolithiasis cases. However, a greater awareness of their phenotypes
will increase clinical suspicion in patients presenting with a typical biochemical profile. Testing
for mutations in CYP24A1 can establish a definitive diagnosis, avoiding protracted further
investigations and allowing treatment to commence. Alongside dietary and lifestyle advice,
aimed at minimising vitamin D intake, fluconazole is proving a promising lifelong treatment
to prevent effects of vitamin D toxicity.
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